AU2003300394A8 - In vivo methods for validating the role of a tumor maintenance gene - Google Patents

In vivo methods for validating the role of a tumor maintenance gene

Info

Publication number
AU2003300394A8
AU2003300394A8 AU2003300394A AU2003300394A AU2003300394A8 AU 2003300394 A8 AU2003300394 A8 AU 2003300394A8 AU 2003300394 A AU2003300394 A AU 2003300394A AU 2003300394 A AU2003300394 A AU 2003300394A AU 2003300394 A8 AU2003300394 A8 AU 2003300394A8
Authority
AU
Australia
Prior art keywords
validating
role
vivo methods
tumor maintenance
maintenance gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003300394A
Other versions
AU2003300394A1 (en
Inventor
Murray O Robinson
Anna Pavlova
Joerg Heyer
Ronald Depinho
Tyler Jacks
Steven C Clark
William Rideout
Ronan C O'hagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Genpath Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genpath Pharmaceuticals Inc filed Critical Genpath Pharmaceuticals Inc
Publication of AU2003300394A1 publication Critical patent/AU2003300394A1/en
Publication of AU2003300394A8 publication Critical patent/AU2003300394A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003300394A 2002-12-24 2003-12-23 In vivo methods for validating the role of a tumor maintenance gene Abandoned AU2003300394A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43649902P 2002-12-24 2002-12-24
US60/436,499 2002-12-24
US45480203P 2003-03-12 2003-03-12
US60/454,802 2003-03-12
PCT/US2003/041358 WO2004058948A2 (en) 2002-12-24 2003-12-23 In vivo methods for validating the role of a tumor maintenance gene

Publications (2)

Publication Number Publication Date
AU2003300394A1 AU2003300394A1 (en) 2004-07-22
AU2003300394A8 true AU2003300394A8 (en) 2004-07-22

Family

ID=32685458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003300394A Abandoned AU2003300394A1 (en) 2002-12-24 2003-12-23 In vivo methods for validating the role of a tumor maintenance gene

Country Status (2)

Country Link
AU (1) AU2003300394A1 (en)
WO (1) WO2004058948A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222590A1 (en) 2005-04-05 2006-10-05 Murray Robinson Directed complementation
CA2728575A1 (en) * 2007-06-29 2009-01-08 Boston Biomedical, Inc. Enabling the use of long dsrna for gene targeting in mammalian and other selected animal cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3214177A3 (en) * 1998-04-08 2017-11-22 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
AU1086501A (en) * 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference

Also Published As

Publication number Publication date
WO2004058948A2 (en) 2004-07-15
AU2003300394A1 (en) 2004-07-22
WO2004058948A3 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
HK1091126A1 (en) Methods for inhibiting viral replication in vivo
EP1482970A4 (en) Cancer therapy
AU2003235470A8 (en) Predictive markers in cancer therapy
EP1497655A4 (en) Enhanced gene expression system
EP1490074A4 (en) Mixed- cell gene therapy
AU2003220387A8 (en) Gene amplification in cancer
EP1667701A4 (en) Tumor vaccine
GB0406728D0 (en) Gene therapy
AU2003249054A8 (en) Neuronal gene expression patterns
AU2003282538A8 (en) Gene regulation with aptamer and modulator complexes for gene therapy
GB0327384D0 (en) Gene therapy
EP1472498A4 (en) Continuous process furnace
IL163379A (en) Continuous cell line for the production of vaccines
AU2003300394A8 (en) In vivo methods for validating the role of a tumor maintenance gene
AU2003288699A8 (en) Method for in vivo sensing
EP1607704A4 (en) Continuous furnace
GB0226595D0 (en) Cancer therapy determination
EP1693069A4 (en) Remedy for solid tumor
AU2003294705A8 (en) Ntsm gene
GB0223982D0 (en) Marker gene
AU2003231937A8 (en) Therapeutic methods
EP1646282A4 (en) Genetic vaccines for cancer therapy
GB0419080D0 (en) Tumour model
GB0224663D0 (en) DNAzyme
AU2003278877A8 (en) Susceptibility gene for human stroke

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase